OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

Basilea Pharmaceutica logo
$84.00 0.00 (0.00%)
As of 11/18/2026

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Advanced

Key Stats

Today's Range
$84.00
▼
$84.00
50-Day Range
$76.25
▼
$84.00
52-Week Range
$59.29
▼
$84.00
Volume
N/A
Average Volume
1 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections.

The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections.

Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships. Availability and marketing arrangements vary by territory.

AI Generated. May Contain Errors.

Basilea Pharmaceutica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

BPMUF MarketRank™: 
1.323108384455 of 5 stars

Basilea Pharmaceutica scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Basilea Pharmaceutica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Basilea Pharmaceutica has only been the subject of 1 research reports in the past 90 days.

  • Read more about Basilea Pharmaceutica's stock forecast and price target.
  • Earnings Growth

    Earnings for Basilea Pharmaceutica are expected to decrease by -10.48% in the coming year, from $8.49 to $7.60 per share.

  • Price to Book Value per Share Ratio

    Basilea Pharmaceutica has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Basilea Pharmaceutica has been sold short.
  • Short Interest Ratio / Days to Cover

    Basilea Pharmaceutica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Basilea Pharmaceutica has recently decreased by 64.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Basilea Pharmaceutica does not currently pay a dividend.

  • Dividend Growth

    Basilea Pharmaceutica does not have a long track record of dividend growth.

  • News Sentiment

    Basilea Pharmaceutica has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Basilea Pharmaceutica this week, compared to 0 articles on an average week.
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BPMUF Stock News Headlines

Brokers Offer Predictions for OTCMKTS:BPMUF FY2026 Earnings
HC Wainwright Estimates OTCMKTS:BPMUF FY2027 Earnings
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

BPMUF Stock Analysis - Frequently Asked Questions

Basilea Pharmaceutica's stock was trading at $63.25 at the start of the year. Since then, BPMUF stock has increased by 32.8% and is now trading at $84.00.

Basilea Pharmaceutica subsidiaries include these companies: Conec UK Limited.

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
189
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.44
Current Ratio
6.60
Quick Ratio
5.97

Sales & Book Value

Annual Sales
$280.43 million
Price / Sales
3.94
Cash Flow
$3.85 per share
Price / Cash Flow
21.82
Book Value
$11.73 per share
Price / Book
7.16

Miscellaneous

Outstanding Shares
13,170,000
Free Float
N/A
Market Cap
$1.11 billion
Optionable
Not Optionable
Beta
0.22

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:BPMUF) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners